Floatz logo

Crs-207

Adenocarcinoma of the Ovaries

Anza Therapeutics, Inc.vaccinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Adenocarcinoma of the Ovaries cohort.

Asset / SponsorPhaseRating
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Niraparib
CanariaBio Inc.
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC

View all 15 →

Same molecule, other indications

Crs-207 is also rated in:

malignant epithelioid mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →